

Beatriz Perdiguero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/610983/publications.pdf>

Version: 2024-02-01

46
papers

2,303
citations

236833

25
h-index

214721

47
g-index

48
all docs

48
docs citations

48
times ranked

3281
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. <i>Vaccines</i> , 2021, 9, 243.	2.1	217
2	Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. <i>Vaccines</i> , 2021, 9, 959.	2.1	11
3	Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant. <i>Journal of Virology</i> , 2020, 95, .	1.5	6
4	Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vecteded by MVA Virus. <i>Vaccines</i> , 2019, 7, 57.	2.1	5
5	A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses. <i>Viruses</i> , 2019, 11, 160.	1.5	12
6	Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2941.	2.2	9
7	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 2793.	2.2	2
8	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
9	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
10	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
11	Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B. <i>Viruses</i> , 2018, 10, 424.	1.5	9
12	Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways. <i>Viruses</i> , 2018, 10, 7.	1.5	9
13	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	26
14	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. <i>PLoS ONE</i> , 2017, 12, e0186602.	1.1	20
15	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
16	NF κ B activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1333-E1342.	3.3	26
17	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	1.5	40
18	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. <i>Journal of Virology</i> , 2015, 89, 3819-3832.	1.5	10

#	ARTICLE	IF	CITATIONS
19	The Evolution of Poxvirus Vaccines. <i>Viruses</i> , 2015, 7, 1726-1803.	1.5	164
20	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	1.3	56
21	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	1.5	35
22	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. <i>Journal of Virology</i> , 2015, 89, 970-988.	1.5	30
23	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. <i>PLoS ONE</i> , 2015, 10, e0141456.	1.1	24
24	Clinical applications of attenuated MVA poxvirus strain. <i>Expert Review of Vaccines</i> , 2013, 12, 1395-1416.	2.0	66
25	New vaccinia virus promoter as a potential candidate for future vaccines. <i>Journal of General Virology</i> , 2013, 94, 2771-2776.	1.3	22
26	High, Broad, Polyfunctional, and Durable T Cell Immune Responses Induced in Mice by a Novel Hepatitis C Virus (HCV) Vaccine Candidate (MVA-HCV) Based on Modified Vaccinia Virus Ankara Expressing the Nearly Full-Length HCV Genome. <i>Journal of Virology</i> , 2013, 87, 7282-7300.	1.5	39
27	Involvement of the Cellular Phosphatase DUSP1 in Vaccinia Virus Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003719.	2.1	23
28	Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C. <i>PLoS ONE</i> , 2013, 8, e74831.	1.1	25
29	Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein. <i>PLoS ONE</i> , 2012, 7, e32220.	1.1	54
30	Poxvirus vectors as HIV/AIDS vaccines in humans. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1192-1207.	1.4	73
31	Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice. <i>Journal of Virology</i> , 2012, 86, 5026-5038.	1.5	38
32	Cryo X-ray nano-tomography of vaccinia virus infected cells. <i>Journal of Structural Biology</i> , 2012, 177, 202-211.	1.3	70
33	Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. <i>PLoS ONE</i> , 2012, 7, e35485.	1.1	30
34	A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity. <i>PLoS ONE</i> , 2012, 7, e42163.	1.1	11
35	Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. <i>PLoS ONE</i> , 2012, 7, e48524.	1.1	30
36	The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. <i>Journal of Virology</i> , 2011, 85, 11468-11478.	1.5	63

#	ARTICLE	IF	CITATIONS
37	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). <i>Vaccine</i> , 2011, 29, 8309-8316.	1.7	70
38	Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors. <i>PLoS ONE</i> , 2011, 6, e16819.	1.1	42
39	Improved NYVAC-Based Vaccine Vectors. <i>PLoS ONE</i> , 2011, 6, e25674.	1.1	59
40	MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer. <i>Current Gene Therapy</i> , 2011, 11, 189-217.	0.9	100
41	Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7131-7136.	3.3	121
42	Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome. <i>PLoS Pathogens</i> , 2009, 5, e1000480.	2.1	285
43	The Interferon System and Vaccinia Virus Evasion Mechanisms. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 581-598.	0.5	141
44	Vaccinia Virus A34 Glycoprotein Determines the Protein Composition of the Extracellular Virus Envelope. <i>Journal of Virology</i> , 2008, 82, 2150-2160.	1.5	22
45	Interaction between Vaccinia Virus Extracellular Virus Envelope A33 and B5 Glycoproteins. <i>Journal of Virology</i> , 2006, 80, 8763-8777.	1.5	36
46	Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein. <i>Journal of General Virology</i> , 2001, 82, 2747-2760.	1.3	96